Humanoid Global Holdings Corp. (RBOHF)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-1.79	-2.07	-1.08	-6.46	-17.16
Depreciation & Amortization	-	-	0	0.01	0.03
Asset Writedown & Restructuring Costs	-	-	-	0.04	-
Loss (Gain) From Sale of Investments	1.67	1.09	-0.43	4.33	13.22
Stock-Based Compensation	-	-	0.13	0.01	0.63
Provision & Write-off of Bad Debts	-	-	0.01	-	-
Other Operating Activities	-0.27	-0.24	-0.59	-0.27	0.34
Change in Accounts Receivable	0.1	-0.04	-0.02	0.08	-0.07
Change in Accounts Payable	0.25	0.35	0.06	-0.05	-0.18
Change in Unearned Revenue	-	-	-	-0.02	-0.13
Change in Other Net Operating Assets	-	-	0.08	-0.03	0.02
Operating Cash Flow	-0.04	-0.72	-0.99	-2.35	-3.3
Short-Term Debt Issued	-	-	0.14	-	-
Long-Term Debt Issued	0.05	-	-	-	-
Total Debt Issued	0.05	-	0.14	-	-
Long-Term Debt Repaid	-0.02	-	-	-0.01	-0.04
Net Debt Issued (Repaid)	0.04	-	0.14	-0.01	-0.04
Issuance of Common Stock	-	0.74	0.01	3.17	2.72
Other Financing Activities	-	-0.02	-	-	0.14
Financing Cash Flow	0.04	0.72	0.15	3.16	2.82
Net Cash Flow	-0	-0	-0.84	0.81	-0.49
Free Cash Flow	-0.04	-0.72	-0.99	-2.35	-3.3
Free Cash Flow Margin	-	-	-228.27%	-	-
Free Cash Flow Per Share	-0.01	-0.19	-0.48	-2.77	-11.73
Levered Free Cash Flow	-1.08	-1.21	-0.16	-3.87	-10.11
Unlevered Free Cash Flow	-1.06	-1.19	-0.15	-3.86	-10.05
Change in Net Working Capital	-0.21	-0.06	-0.36	0.23	0.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.